Moderate

Myelodysplastic syndrome (MDS; myelodysplasia, preleukaemia)

Bone marrow failure / clonal · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Clonal stem-cell disorders causing ineffective haematopoiesis -> cytopenias with dysplastic, usually hypercellular marrow, and risk of AML transformation. Older adults with unexplained anaemia +/- neutropenia/thrombocytopenia. ED role: manage cytopenic complications (anaemia, infection, bleeding) and refer; distinguish from reversible causes.

Red flags

  • Febrile neutropenia (treat as sepsis immediately)
  • Rising blast percentage / circulating blasts (AML transformation)
  • Severe thrombocytopenia with bleeding
  • Rapidly progressive pancytopenia
  • New symptomatic severe anaemia

Assessment

Differential diagnosis

  • Reversible cytopenias: B12/folate deficiency, copper deficiency, alcohol, drugs, viral (HIV), autoimmune
  • Aplastic anaemia / PNH
  • Acute leukaemia (blasts >=20%)
  • Myelofibrosis / MDS-MPN overlap (e.g. CMML)
  • Marrow infiltration by lymphoma/carcinoma

Investigations

  • FBC + reticulocytes + blood film (oval macrocytes, hypogranular/hypolobated neutrophils - pseudo-Pelger-Huet, blasts)
  • B12, folate, ferritin, TFTs, LFTs, copper, HIV (exclude reversible causes) before labelling MDS
  • Bone marrow aspirate + trephine: dysplasia, blast %, ring sideroblasts; cytogenetics (e.g. del(5q), -7); molecular panel
  • Reticulocyte count, haptoglobin/LDH (exclude haemolysis)
  • Risk score: IPSS-R / IPSS-M (prognosis and treatment)
  • Group & screen, viral serology (pre-transfusion/transplant)

Management

  • Exclude and correct reversible causes of cytopenia first
  • Manage acute complications: transfuse symptomatic anaemia; treat neutropenic fever as sepsis; manage bleeding from thrombocytopenia
  • Risk-stratify (IPSS-R) - low-risk: supportive care +/- ESA; high-risk: hypomethylating agent or transplant assessment
  • Iron chelation if chronically transfusion-dependent and ongoing need (low-risk, ferritin very high)
  • del(5q) syndrome: lenalidomide
  • Assess allogeneic transplant eligibility in higher-risk, fit patients
  • Vaccinate; counsel on infection/bleeding precautions

Drugs & doses

Transfuse packed red cells for symptomatic anaemia (restrictive threshold); platelets for bleeding/very low counts
Erythropoiesis-stimulating agent (epoetin/darbepoetin) for low-risk anaemia with low endogenous EPO [verify local dose]
Azacitidine 75 mg/m2 SC/IV daily x7 days every 28 days (higher-risk MDS) [verify local dose]
Lenalidomide 10 mg PO once daily (del(5q) MDS) [verify local dose]
Iron chelation - deferasirox per weight if transfusion iron overload [verify local dose]
Broad-spectrum antibiotics per neutropenic sepsis protocol for febrile neutropenia
Allogeneic stem cell transplant - only curative option (eligible higher-risk patients)

Disposition

Febrile neutropenia / severe bleeding / symptomatic anaemia -> admit. Stable -> outpatient haematology for marrow, risk scoring and treatment.

Complications & pitfalls

  • Transformation to acute myeloid leukaemia
  • Infection from neutropenia (leading cause of death)
  • Bleeding from thrombocytopenia
  • Transfusional iron overload
  • Transfusion dependence

Exam pearls

  • Always exclude B12/folate/copper deficiency, HIV and drugs before diagnosing MDS - these are reversible
  • IPSS-R/IPSS-M drives management: supportive for low-risk, hypomethylating/transplant for high-risk
  • A febrile neutropenic MDS patient needs antibiotics within 1 hour - do not wait for cultures
  • del(5q) MDS responds well to lenalidomide
  • Macrocytic anaemia in an older adult with a normal B12/folate deserves a film and marrow

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.